Neuromuscular disorders have multifaceted symptoms which change over the course of disease. Patient assessment typically occurs in person through routine care by a neuromuscular subspecialist. Such in-clinic assessments may be subjective, providing only a snapshot of a patient’s disease. They may not capture weakness or symptoms which affect patient’s day-to-day quality of life. _x000D_
_x000D_
Frequent monitoring and assessment of disease manifestations are critical for evaluating natural history, and the effects of interventions or drugs at multiple time points. Significant investment and progress have been made in developing remote monitoring and telehealth solutions in several areas of medicine (e.g., cardiovascular and infectious diseases). However, similar solutions are lacking for neuromuscular diseases. To address this need, we have developed robust and easy-to-use remote monitoring and telehealth solutions for neurological and neuromuscular diseases, called BioDigit Home and BioDigit Mobile. The solutions enable remote assessment of motor, speech and cognitive functions using wearable sensors and digital clinical assessments. By reducing patient and caregiver burden, applications of remote monitoring solutions may be able to increase access to care and clinical trials. _x000D_
_x000D_
BioDigit Home and BioDigit Mobile are currently being used in multiple investigator-initiated, NIH-funded projects, and pharma-sponsored drug trials to collect digital measures of disease manifestations and/or change. During the presentation, we will present results from studies in myasthenia gravis and motor neuron disease that are being conducted in collaboration with Massachusetts General Hospital, and Penn State College of Medicine, respectively. _x000D_
_x000D_
Acknowledgements _x000D_
Research reported in this publication was supported in part by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number R44NS122672 and in part with Federal funds from the National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N95022C00040. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.